Latest ALS Clinical Trial Information

ALS is the third most common neurodegenerative disease after Alzheimer’s and Parkinson’s diseases. The worldwide ALS prevalence is 4.42 per 1,00,000 people. (Xu et al., 2020) The onset of the disease is most common in people in their 40s to 70s, and 90% of cases occur without any family history of the disease. However, approximately 10% of these cases are familial ALS.

Once the disease develops, the patient gradually becomes immobile, has difficulty eating and speaking, and is unable to breathe. A ventilator can sustain life, but paralysis progresses throughout the body. The average life expectancy with a ventilator is 7 years. (Hayashi et al., 2020)

Unfortunately, there is no curative therapy; however, there are drugs that can delay the time to ventilator use by a few months. Only the motor nerves are affected (degenerated), and patients gradually lose the ability to move their bodies while remaining conscious. The disease is also characterized by a very heavy burden of nursing care, as the patient requires around-the-clock care.

There are several ongoing studies worldwide to achieve a fundamental cure.

This website provides the latest information on ALS clinical trials, based on scientific evidence.

---

Daisuke Ito M.D. Ph.D.
Specially Appointed Professor
Department of Physiology/Memory center
Keio University School of Medicine
35 Shinanomachi, Shinjuku-ku,
Tokyo 160-8582, Japan
https://keio-memory-clinic.com

https://www.facebook.com/profile.php?id=100053750162768
https://scholar.google.co.jp/citations?user=gG_vhz4AAAAJ&hl=ja&oi=ao
https://twitter.com/3j06dHE8OsjdGwL

Cooperation

Kensuke Okada

#The following are the criteria for clinical trials to be considered:

1) There is a reliable preclinical study

2) Phase II or higher in principle

3) High social and medical importance Last update　June 17, 2022